United States
Endothelial Progenitor Cells
Have a question or just need help?
Contact us for Service and Support

Endothelial Progenitor Cells

Introduction to Endothelial Progenitor Cells

Endothelial Progenitor Cells (EPC) play an important role in the process of both angiogenesis and vasculogenesis. Compared to specific mature types of endothelial cells such as HMVEC and HUVEC, EPCs are more suitable for cell-based screening of anti-cancer drugs. In addition, EPCs have an impact on aging, suggesting the potential use of EPCs in these areas. BioChain's EPCs are a primitive cell type in the endothelial lineage. They are derived from bone marrow and have properties similar to those of embryonic angioblasts. These progenitor cells migrate into the blood stream and are able to differentiate into a variety of mature vascular endothelial cell types.


  • Primary cells
  • CD 133+ resuspension cells
  • Progenitor cells, not terminally differentiated mature endothelial cells such as HUVEC and HMVEC
  • Capable of differentiating into specific subtypes of endothelial cells, change to CD 133- when attached to the cell culture vessel
  • Gene expression pattern similar to that of endothelial cells from tumors
  • Specifically migrate to tumors
  • Quantity and functions in the blood is altered during pathogenesis of a variety of diseases
  • Applications

    EPC is a unique primitive cell type and is involved in a variety of human diseases. Isolated EPC cells can be used in research and drug discovery in the following areas:
  • Cancers such as lymphoma, breast cancer, lung cancer and inoperable heptocellular carcinoma (HCC)
  • Vascular diseases such as coronary artery disease (CAD) and acute myocardial infarction
  • Diabetes Mellitus
  • Ischemia
  • Pulmonary hypertension
  • Cerebral vascular disease
  • Arthritis
  • Cutaneous wound healing and skin regeneration